Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash from Financing Activities (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Cash from Financing Activities for 12 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1030.25% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 14.67% decrease, with the full-year FY2025 number at $6.6 million, down 14.67% from a year prior.
  • Cash from Financing Activities was $2.9 million for Q4 2025 at Ekso Bionics Holdings, up from -$437000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $38.7 million in Q1 2021 to a low of -$437000.0 in Q3 2025.
  • A 4-year average of $5.3 million and a median of $1.8 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 6672.5% in 2021, then crashed 190.23% in 2024.
  • Ekso Bionics Holdings' Cash from Financing Activities stood at $38.7 million in 2021, then tumbled by 99.1% to $348000.0 in 2023, then crashed by 190.23% to -$314000.0 in 2024, then surged by 1030.25% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Cash from Financing Activities are $2.9 million (Q4 2025), -$437000.0 (Q3 2025), and $616000.0 (Q2 2025).